12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Talimogene laherparepvec: Additional Phase III data

Additional data from an open-label, international Phase III trial in >400 patients with unresectable stage IIIB, IIIC or IV melanoma showed that talimogene laherparepvec led to an overall response rate (ORR) of 26% vs. 6% for GM-CSF. Amgen said data for the secondary endpoint...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >